Penn Medicine Abramson Cancer Center


 

ASH 2019 AML Update: Maintenance Therapy is Likely to Become Standard - Update on Trials with Oral Azacitidine & Gilteritinib

0 views
February 24, 2020
Comments 1
Login to view comments. Click here to Login